Aesthetic manufacturer Marllor Biomedical has entered an exclusive distribution agreement with aesthetic distributor Wigmore Medical.
According to the company, the agreement will see Wigmore Medical distribute the Marllor Biomedical non-surgical aesthetic products Aqualyx and Alidya. Aqualyx is an injectable treatment used to target localised fat deposits in non-surgical body contouring procedures and has been on the market for more than 15 years. Alidya is an injectable product developed for the prevention and treatment of cellulite, designed to address underlying tissue changes associated with the condition, according to Wigmore Medical.
Martina Motolese, chief operating officer at Marllor Biomedical, commented, “This partnership signifies more than distribution, it reflects a shared commitment to clinical excellence, responsible innovation and long-term brand building. Together, we aim to further elevate treatment standards, support practitioners through high-level education and expand patient awareness of evidence-based body treatments.”